Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Rana R. McKay, MD, discusses patient selection and the treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC).
Read MoreSelect Page
Posted by Rana R. McKay, MD | Apr 2023
Rana R. McKay, MD, discusses patient selection and the treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC).
Read MorePosted by Sigrid V. Carlsson, MD, PhD, MPH | Apr 2023
Sigrid V. Carlsson, MD, PhD, MPH discusses prostate cancer screening, focusing on PSA screening, risk calculators, biomarkers, and MRI.
Read MorePosted by Seth P. Lerner, MD, FACS | Apr 2023
Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.
Read MorePosted by Martin M. Miner, MD | Apr 2023
Martin M. Miner, MD, discusses the role of testosterone therapy in improving men’s health outcomes, including in prostate cancer.
Read MorePosted by Wesley A. Mayer, MD | Apr 2023
Wesley A. Mayer, MD, and Marisa M. Clifton, MD, FACS, FPMRS, debate residency training and ponder whether faculty are too hard or too soft on residents.
Read More